Prostate Specific Antigen, Total - Medicare Screening
Preferred initial screening test for prostate cancer in conjunction with digital rectal exam. May use to monitor patients for recurrence of cancer.
Quantitative Electrochemiluminescent Immunoassay
Within 24 hours
New York DOH Approval Status
This test is New York DOH approved.
- Patient Preparation
- Serum separator tube or plasma separator tube. Also acceptable: Plain red, green (sodium or lithium heparin), lavender (EDTA), or pink (K2EDTA).
- Specimen Preparation
- Transport 1 mL serum or plasma. (Min: 0.5 mL)
- Storage/Transport Temperature
- Unacceptable Conditions
- Hemolyzed specimens.
- Ambient: 8 hours; Refrigerated: 5 days; Frozen: 6 months
The Roche PSA electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma.
This test should be ordered for screening purposes for Medicare patients only.
|Component Test Code*||Component Chart Name|
|0070234||Prostate Spec Ag Total Screen|